No Detail Found!

Effcacy and Safety of Combined Chemotherapy Regimens with Bevacizumab in Platinum-sensitive Ovarian Cancers

Author(s)
Fatih Tay Department of Medical Oncology, Health Sciences University, Dr. A.Y. Ankara Oncology Training and Research Hospital,Ankara,Turkey
Mustafa Buyukkor Department of Medical Oncology, Health Sciences University, Dr. A.Y. Ankara Oncology Training and Research Hospital,Ankara,Turkey
Ozturk Ates Department of Medical Oncology, Health Sciences University, Dr. A.Y. Ankara Oncology Training and Research Hospital,Ankara,Turkey
Abstract
Objective: To determine the di erences in terms of overall survival in platinum-sensitive ovarian cancer (PSOC) patients undergoing various chemotherapy protocols, and to demonstrate patient tolerance, toxicity, and e cacy data with the use of bevacizumab in di erent protocols. Study Design: An observational study. Place and Duration of the Study: Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey, from January 2018 to January 2022. Methodology: Patients aged 18 and above, who had received treatment for PSOC, were included in the study. Patients with platinum-resistant disease and those for whom bevacizumab usage was contraindicated were not enrolled in the study. Results: For the 95 patients, the median age was 55 (34-78) years. Median follow-up are 39.7 (39.2-47.5) months. Median progression-free survival (PFS) of the patients are 10.8 (7.3-14.0) months for carboplatin-gemcitabine-bevacizumab (CGB), 10.9 (IQR 5.5-14.3) months in the carboplatin-liposomal doxorubicin-bevacizumab (CLdB) arms, and 6.1 (IQR 5.8-14.3) months in the carboplatin-paclitaxel-bevacizumab (CPB) group (p=0.79). The median overall survivals (OS) are 37.9 (IQR 33.3-46.9) months in the CGB arm, 41.0 (IQR 38.0-50.3) months CPB arm, and 41.3 (IQR 38.1-52.3) months in the CLdB arm (p=0.173). Conclusion: There was no di erence in terms of overall survival among all three chemotherapy protocols. However, due to the di erence in toxicity, the treatment should be selected on a patient-speci c basis. Additionally, the use of bevacizumab at a dose of 7.5 mg/kg was demonstrated to be equivalent to using 15 mg/kg in terms of overall survival. This lower dose is also important to avoid nancial toxicity.
Publication Details
Page(s) 1006-1011
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 33, Issue: 9, Year: 2023

Request the full text from PASTIC

Keywords
Bevacizumab, Ovarian cancer, Tolerability, Adverse clinical events, Platinum-based chemotherapy
0

Citations

0

Downloads

59

Views